FOR IMMEDIATE RELEASE: 2021/11/10“Medical Marketer” Service Tops Adoption by Over 100 Drugs~ “Remote x Data x Personnel Pharma” Sales and Marketing Productivity Support Service ~M3, Inc. (Headquarter: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3,”below) has announced that “Medical Marketer” (“MM,” below) and the “Medical Marketer Platform”(“MMP,” below) a sales and marketing support service for pharmaceuticals and medical device
manufacturers, has been adopted by more than a cumulative of 100 drugs.
MMs are M3’s sales representatives equipped with digital tools and a thorough understanding ofanalysis and remote detailing.

One MM communicates with 500 ~ 1,500 doctors, making full useof text messages and web meeting tools on “m3.com.”

m3.com is a dedicated platform for

healthcare professionals which holds memberships of 300,000 doctors.
information provision.

It is not a standard

Through analysis of big data regarding M3’s physician members, MMs areable to improve detailing tactics speedily to create high impact on prescriptions by actioning
individually optimized 2-way communication.

Productivity of MRs are overwhelming compared toconventional MR activities – 10 fold in coverage of doctors with 10 to 20 times the detailing amount.

MM and MMP usage has expanded significantly every year after the service launch and it has been
introduced to cover a cumulative of 50 companies exceeding 100 drug.

Services are used by avariety of clients, including domestic/foreign companies in different sizes.

Further, it is being utilized

across various drugs, from primary care to specialty areas such as oncology and orphan therapy
areas as well as new, and late stage drugs.

Furthermore, COVID has impacted a strong movement towards fortification of remote detailingpersonnel by pharma companies. Due to this backdrop, MMP, which assists in replicating theproductivity of M3’s MMs for the internal sales representatives of pharma companies, has been
rapidly expanding, with the number of projects growing six-fold over the past year.

M3’s otherservice, myMR-kun, is also provided as a service to promote DX of all pharmaceutical sales reps
(utilized by over 30 companies) has strong affinity with MMP, with the combination of both creating a
dedicated and comprehensive remote detailing structure.

More pharma companies are utilizing

both services, with largely 3 usage patterns:(1) Product axis: Allocate MR (geared with myMR-kun) resources to new drugs.

Suppress

revenue decrease of drugs in late stages efficiently with MMP.
(2) Physician axis: Allocate MRs (geared with myMR-kun) resources to core target doctors.

Forother doctors, proceed with communication upon determination of targeting priority via MMP dataanalysis(3) Usage axis: For the same target doctors, MMP to initially handle he initial sales pitch, thenescalate to MRs (geared with my MR-kun) in the field sales teamWe have receive the following comments from management of companies that have implemented
MM projects:■ Mr. Torsten KanischExecutive Officer
Vice President, Commercial Excellence
AstraZeneca K.K.
“As face to face appointments with HCPs have become more difficult due to the spread of COVID19, the Medical Marketer (MM) solution enables us to immediately engage with a broad HCP
audience and provide relevant information flexibly according to our customers’ needs.
Moreover, MMs effectively connect with in-field MRs to create follow through and conversation
continuity.
We consider MM as one of our key solutions in digital transformation of our promotional activities.”■ Mr. Kei Bamba
Executive director
Head of Specialty Care Business Unit, Corporate Officer
Amgen K.K.
“Under the covid-19 environment, the application of digital channel is becoming more important forcustomer engagement. In order to achieve our corporate mission “To Serve Patients” and to
improve patients’ outcome, it has been already obvious that we need to construct new customer
engagement model connecting offline and online seamlessly including this solution (MedicalMarketer). Furthermore, we are thinking that a new phase has already arrived where the quality,that is, effectiveness and efficiency, should be an issue.”M3 will continue to evolve and promote usage of internet-based digitalization services starting with
MM and MMP, to support the DX of sales and marketing which is currently one of the highest
priorities for pharmaceutical companies, and ultimately contribute to the structural transformation of
the pharmaceutical industry.